J Clin Oncol 2021 Jan 13
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133).
ABSTRACT
PURPOSE
IMpower133 (ClinicalTrials.gov identifier: NCT02763579), a randomized, double-blind, phase I/III study, demonstrated that adding atezolizumab (anti-programmed death-ligand 1 [PD-L1]) to carboplatin plus etoposide (CP/ET) for first-line (1L) treatment of extensive-stage small-cell lung cancer (ES-SCLC) resulted in significant improvement in overall survival (OS) and progression-free survival (PFS) versus placebo plus CP/ET. Updated OS, disease progression patterns, safety, and exploratory biomarkers (PD-L1, blood-based tumor mutational burden [bTMB]) are reported.
PATIENTS AND METHODS
Patients with untreated ES-SCLC were randomly assigned 1:1 to receive four 21-day cycles of CP (area under the curve 5 mg per mL/min intravenously [IV], day 1) plus ET (100 mg/m IV, days 1-3) with atezolizumab (1,200 mg IV, day 1) or placebo, and then maintenance atezolizumab or placebo until unacceptable toxicity, disease progression, or loss of clinical benefit. Tumor specimens were collected; PD-L1 testing was not required for enrollment. The two primary end points, investigator-assessed PFS and OS, were statistically significant at the interim analysis. Updated OS and PFS and exploratory biomarker analyses were conducted.
RESULTS
Patients received atezolizumab plus CP/ET (n = 201) or placebo plus CP/ET (n = 202). At the updated analysis, median follow-up for OS was 22.9 months; 302 deaths had occurred. Median OS was 12.3 and 10.3 months with atezolizumab plus CP/ET and placebo plus CP/ET, respectively (hazard ratio, 0.76; 95% CI, 0.60 to 0.95; descriptive = .0154). At 18 months, 34.0% and 21.0% of patients were alive in atezolizumab plus CP/ET and placebo plus CP/ET arms, respectively. Patients derived benefit from the addition of atezolizumab, regardless of PD-L1 immunohistochemistry or bTMB status.
CONCLUSION
Adding atezolizumab to CP/ET as 1L treatment for ES-SCLC continued to demonstrate improved OS and a tolerable safety profile at the updated analysis, confirming the regimen as a new standard of care. Exploratory analyses demonstrated treatment benefit independent of biomarker status.
Related Questions
Are you routinely performing molecular sequencing? Would you modify your treatment approach in first or later lines based on PDL1 status?
New answer by Medical Oncologist at Northwestern Medicine Cancer Center at KishHealth (May 6, 2021)
Unless you test you will never find it. Certain tumor agnostic therapies such as for NTRK can be useful to patients. I will test for good performance status at progression and...
Would you differentiate between patients with measurable disease vs NED? Are there specific data to guide us?
New answer by Medical Oncologist at Rush University Medical Center (March 5, 2021)
I know of no data to guide stopping points for patients with extensive stage SCLC who have had exceptional responses to chemo-immunotherapy. My practice is to check a PE...
E.g. chemo/durvalumab vs chemo/atezolizumab?
New answer by Medical Oncologist at Rush University Medical Center (March 5, 2021)
Both the addition of durvalumab and atezolizumab to platinum etoposide resulted in a modest improvement in median progression free, overall survival and saw twelve-month overa...